Middle East Professional Acne Medication Market by Acne Type (Inflammatory Acne and Non-inflammatory Acne), by Formulation (Topical Medications and Oral Medications), by Therapeutic Class (Retinoids, Antibiotics, Salicylic Acid, Benzoyl Peroxide, and Others), and by Distribution Channel (Med Spa, Aesthetician, Dermatologist, and Other Professional Channels) – Opportunity Analysis and Industry Forecast, 2024–2030

Middle East Professional Acne Medication Market

Industry:  Consumer Goods | Publish Date: Dec 2023 | No of Pages:  400 | No. Tables:  77 | No. Figures:  42

Market Definition

Middle East Professional Acne Medication Market was valued at USD 74.66 million in 2023 and is predicted to reach USD 125.73 million by 2030, with a CAGR of 7.7% from 2024 to 2030. The professional acne medicine market refers to dermatologist-prescribed specialist skincare formulations for focused and effective acne therapy, treating both inflammatory and non-inflammatory lesions while reducing scarring. These formulations provide benefits such as powerful and customized chemicals, frequently outperforming over-the-counter alternatives.

Professional acne treatments, which are widely used in dermatological services, cater to those who have severe or persistent acne problems, assuring a better degree of efficacy and control. As the demand for advanced skincare grows, this industry will remain critical in delivering tailored and medically guided ways to cleaner, healthier skin.

Increasing Beauty Awareness with Emphasis on Cosmetic Dermatology Fuels the Growth of Market

The Middle East experienced a notable surge in the demand for cosmetic dermatology treatments, significantly boosting the growth of the professional acne medication market. The region's residents place a strong emphasis on achieving clear and flawless skin, driven by cultural and aesthetic preferences. This growing beauty awareness has led individuals to increasingly seek dermatological solutions for their skincare needs, creating a robust market for professional acne medication.

 

Growing Demand for Professional Acne Care Drives the Market

The Middle East is witnessing a cultural shift with an increasing emphasis on personal appearance and well-being. This shift fuelled a growing demand for professional acne treatments in the region as individuals increasingly seek clear, healthy skin and invest in their overall appearance. The popularity of cosmetic dermatology procedures, including professional acne medication, is on the rise. Patients are opting for advanced treatments such as laser therapy and chemical peels, contributing to the expansion of the professional acne medication market in the Middle East. This trend aligns with the region's evolving beauty and wellness consciousness, highlighting the attractiveness of professional dermatological care and driving market growth. 

 

High Cost Associated with Professional Acne Medication is Restraining the Market Growth

The high cost associated with professional acne treatments poses a significant obstacle to market growth in the Middle East. Many individuals find these treatments financially burdensome, deterring them from seeking professional dermatological care. The out-of-pocket expenses for these services, including consultations, medications, and procedures, can be considerable, making them less accessible to a substantial portion of the population. 

AI Integration Creat.es Growth Opportunity for the Market

The Middle East presents an exciting opportunity for the transformation of dermatology through the integration of artificial intelligence (AI) into acne treatment. This innovative approach involves developing AI algorithms that can assist dermatologists in diagnosing and treating acne more accurately and efficiently. As AI technology becomes more sophisticated and accessible, it has the potential to significantly enhance the quality of acne treatments, streamline the diagnostic process, and improve patient outcomes. Patients in the Middle East can benefit from personalized and innovative solutions for their skincare needs. By leveraging the power of AI, the Middle East is poised to make substantial advancements in the field of acne treatment, promising a future where dermatological care is more effective, accessible, and patient-centric.

 

Competitive Landscape

Middle East professional acne medication market includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

Middle East Professional Acne Medication Market Key Segments

By Acne Type    

  • Inflammatory Acne 

  • Non-inflammatory Acne 

By Formulation    

  • Topical Medications

  • Oral Medications 

By Therapeutic Class

  • Retinoids

  • Antibiotics

  • Salicylic Acid

  • Benzoyl Peroxide

  • Others

By Distribution Channel

  • Med Spa

  • Aesthetician

  • Dermatologist

  • Other Professional Channels

REPORT SCOPE AND SEGMENTATION:

Parameters

Details

Market Size in 2023

USD 74.66 Million

Revenue Forecast in 2030

USD 125.73 Million

Growth Rate

CAGR of 7.7% from 2024 to 2030

Analysis Period

2023–2030

Base Year Considered

2023

Forecast Period

2024–2030

Market Size Estimation

Million (USD)

Growth Factors

Increasing beauty awareness with emphasis on cosmetic dermatology.

Growing demand for professional acne treatments.

 Key Market Players

10

Market Share

Available for 10 companies

Customization Scope

Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.

Pricing and Purchase Options

Avail customized purchase options to meet your exact research needs.

Test

1      INTRODUCTION

           1.1      REPORT DESCRIPTION

           1.2      RESEARCH METHODOLOGY

                         1.2.1      SECONDARY RESEARCH

                         1.2.2      DATA ANALYSIS FRAMEWORK

                         1.2.3      MARKET SIZE ESTIMATION

                         1.2.4      FORECASTING

                         1.2.5      PRIMARY RESEARCH AND DATA VALIDATION

2       MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET BY ACNE TYPE

           2.1      OVERVIEW

           2.2      INFLAMMATORY ACNE MARKET

           2.3      NON-INFLAMMATORY ACNE MARKET

3       MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET BY FORMULATION

           3.1      OVERVIEW

           3.2      TOPICAL MEDICATIONS MARKET

           3.3      ORAL MEDICATIONS MARKET

4       MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET BY THERAPEUTIC CLASS

           4.1      OVERVIEW

           4.2      RETINOIDS MARKET

           4.3      ANTIBIOTICS MARKET

           4.4      SALICYLIC ACID MARKET

           4.5      BENZOYL PEROXIDE MARKET

           4.6      OTHERS MARKET

5       MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET BY DISTRIBUTION CHANNEL

           5.1      OVERVIEW

           5.2      MED SPA MARKET

           5.3      AESTHETICIAN MARKET

           5.4      DERMATOLOGIST MARKET

           5.5      OTHER PROFESSIONAL CHANNELS MARKET

6   COMPANY PROFILES

           6.1   ALMIRALL SA

                         6.1.1   COMPANY OVERVIEW

                         6.1.2   COMPANY SNAPSHOT

                         6.1.3   OPERATING BUSINESS SEGMENTS

                         6.1.4   PRODUCT PORTFOLIO

                         6.1.5   BUSINESS PERFORMANCE

                         6.1.6   BUSINESS SEGMENTS

                         6.1.7   GEOGRAPHIC SEGMENTS

                         6.1.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.1.9   PRIMARY MARKET COMPETITORS

           6.2   BAUSCH HEALTH COMPANIES, INC.

                         6.2.1   COMPANY OVERVIEW

                         6.2.2   COMPANY SNAPSHOT

                         6.2.3   OPERATING BUSINESS SEGMENTS

                         6.2.4   PRODUCT PORTFOLIO

                         6.2.5   BUSINESS PERFORMANCE

                         6.2.6   BUSINESS SEGMENTS

                         6.2.7   GEOGRAPHIC SEGMENTS

                         6.2.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.2.9   PRIMARY MARKET COMPETITORS

           6.3   GLAXOSMITHKLINE PLC (GSK)

                         6.3.1   COMPANY OVERVIEW

                         6.3.2   COMPANY SNAPSHOT

                         6.3.3   OPERATING BUSINESS SEGMENTS

                         6.3.4   PRODUCT PORTFOLIO

                         6.3.5   BUSINESS PERFORMANCE

                         6.3.6   BUSINESS SEGMENTS

                         6.3.7   GEOGRAPHIC SEGMENTS

                         6.3.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.3.9   PRIMARY MARKET COMPETITORS

           6.4   GALDERMA S.A.

                         6.4.1   COMPANY OVERVIEW

                         6.4.2   COMPANY SNAPSHOT

                         6.4.3   OPERATING BUSINESS SEGMENTS

                         6.4.4   PRODUCT PORTFOLIO

                         6.4.5   BUSINESS PERFORMANCE

                         6.4.6   BUSINESS SEGMENTS

                         6.4.7   GEOGRAPHIC SEGMENTS

                         6.4.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.4.9   PRIMARY MARKET COMPETITORS

           6.5   SUN PHARMACEUTICAL INDUSTRIES LIMITED

                         6.5.1   COMPANY OVERVIEW

                         6.5.2   COMPANY SNAPSHOT

                         6.5.3   OPERATING BUSINESS SEGMENTS

                         6.5.4   PRODUCT PORTFOLIO

                         6.5.5   BUSINESS PERFORMANCE

                         6.5.6   BUSINESS SEGMENTS

                         6.5.7   GEOGRAPHIC SEGMENTS

                         6.5.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.5.9   PRIMARY MARKET COMPETITORS

           6.6   TEVA PHARMACEUTICAL INDUSTRIES LTD.

                         6.6.1   COMPANY OVERVIEW

                         6.6.2   COMPANY SNAPSHOT

                         6.6.3   OPERATING BUSINESS SEGMENTS

                         6.6.4   PRODUCT PORTFOLIO

                         6.6.5   BUSINESS PERFORMANCE

                         6.6.6   BUSINESS SEGMENTS

                         6.6.7   GEOGRAPHIC SEGMENTS

                         6.6.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.6.9   PRIMARY MARKET COMPETITORS

           6.7   JOHNSON AND JOHNSON

                         6.7.1   COMPANY OVERVIEW

                         6.7.2   COMPANY SNAPSHOT

                         6.7.3   OPERATING BUSINESS SEGMENTS

                         6.7.4   PRODUCT PORTFOLIO

                         6.7.5   BUSINESS PERFORMANCE

                         6.7.6   BUSINESS SEGMENTS

                         6.7.7   GEOGRAPHIC SEGMENTS

                         6.7.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.7.9   PRIMARY MARKET COMPETITORS

           6.8   STRATA SKIN SCIENCES, INC.

                         6.8.1   COMPANY OVERVIEW

                         6.8.2   COMPANY SNAPSHOT

                         6.8.3   OPERATING BUSINESS SEGMENTS

                         6.8.4   PRODUCT PORTFOLIO

                         6.8.5   BUSINESS PERFORMANCE

                         6.8.6   BUSINESS SEGMENTS

                         6.8.7   GEOGRAPHIC SEGMENTS

                         6.8.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.8.9   PRIMARY MARKET COMPETITORS

           6.9   MAYNE PHARMA GROUP LIMITED

                         6.9.1   COMPANY OVERVIEW

                         6.9.2   COMPANY SNAPSHOT

                         6.9.3   OPERATING BUSINESS SEGMENTS

                         6.9.4   PRODUCT PORTFOLIO

                         6.9.5   BUSINESS PERFORMANCE

                         6.9.6   BUSINESS SEGMENTS

                         6.9.7   GEOGRAPHIC SEGMENTS

                         6.9.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.9.9   PRIMARY MARKET COMPETITORS

           6.10   PFIZER, INC.

                         6.10.1   COMPANY OVERVIEW

                         6.10.2   COMPANY SNAPSHOT

                         6.10.3   OPERATING BUSINESS SEGMENTS

                         6.10.4   PRODUCT PORTFOLIO

                         6.10.5   BUSINESS PERFORMANCE

                         6.10.6   BUSINESS SEGMENTS

                         6.10.7   GEOGRAPHIC SEGMENTS

                         6.10.8   KEY STRATEGIC MOVES AND DEVELOPMENT

                         6.10.9   PRIMARY MARKET COMPETITORS

LIST OF TABLES

TABLE 1. MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

TABLE 2. INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 3. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 4. MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

TABLE 5. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 6. ORAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 7. MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

TABLE 8. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 9. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 10. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 11. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 12. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 13. MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

TABLE 14. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 15. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 16. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 17. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

TABLE 18. ALMIRALL SA: COMPANY SNAPSHOT

TABLE 19. ALMIRALL SA: OPERATING BUSINESS SEGMENTS

TABLE 20. ALMIRALL SA: PRODUCT PORTFOLIO

TABLE 21. ALMIRALL SA: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 22. ALMIRALL SA: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 23. ALMIRALL SA: KEY STRATERGY

TABLE 24. BAUSCH HEALTH COMPANIES, INC.: COMPANY SNAPSHOT

TABLE 25. BAUSCH HEALTH COMPANIES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 26. BAUSCH HEALTH COMPANIES, INC.: PRODUCT PORTFOLIO

TABLE 27. BAUSCH HEALTH COMPANIES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 28. BAUSCH HEALTH COMPANIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 29. BAUSCH HEALTH COMPANIES, INC.: KEY STRATERGY

TABLE 30. GLAXOSMITHKLINE PLC (GSK): COMPANY SNAPSHOT

TABLE 31. GLAXOSMITHKLINE PLC (GSK): OPERATING BUSINESS SEGMENTS

TABLE 32. GLAXOSMITHKLINE PLC (GSK): PRODUCT PORTFOLIO

TABLE 33. GLAXOSMITHKLINE PLC (GSK): SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 34. GLAXOSMITHKLINE PLC (GSK): SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 35. GLAXOSMITHKLINE PLC (GSK): KEY STRATERGY

TABLE 36. GALDERMA S.A.: COMPANY SNAPSHOT

TABLE 37. GALDERMA S.A.: OPERATING BUSINESS SEGMENTS

TABLE 38. GALDERMA S.A.: PRODUCT PORTFOLIO

TABLE 39. GALDERMA S.A.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 40. GALDERMA S.A.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 41. GALDERMA S.A.: KEY STRATERGY

TABLE 42. SUN PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT

TABLE 43. SUN PHARMACEUTICAL INDUSTRIES LIMITED: OPERATING BUSINESS SEGMENTS

TABLE 44. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO

TABLE 45. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 46. SUN PHARMACEUTICAL INDUSTRIES LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 47. SUN PHARMACEUTICAL INDUSTRIES LIMITED: KEY STRATERGY

TABLE 48. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT

TABLE 49. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING BUSINESS SEGMENTS

TABLE 50. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

TABLE 51. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 52. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 53. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGY

TABLE 54. JOHNSON AND JOHNSON: COMPANY SNAPSHOT

TABLE 55. JOHNSON AND JOHNSON: OPERATING BUSINESS SEGMENTS

TABLE 56. JOHNSON AND JOHNSON: PRODUCT PORTFOLIO

TABLE 57. JOHNSON AND JOHNSON: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 58. JOHNSON AND JOHNSON: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 59. JOHNSON AND JOHNSON: KEY STRATERGY

TABLE 60. STRATA SKIN SCIENCES, INC.: COMPANY SNAPSHOT

TABLE 61. STRATA SKIN SCIENCES, INC.: OPERATING BUSINESS SEGMENTS

TABLE 62. STRATA SKIN SCIENCES, INC.: PRODUCT PORTFOLIO

TABLE 63. STRATA SKIN SCIENCES, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 64. STRATA SKIN SCIENCES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 65. STRATA SKIN SCIENCES, INC.: KEY STRATERGY

TABLE 66. MAYNE PHARMA GROUP LIMITED: COMPANY SNAPSHOT

TABLE 67. MAYNE PHARMA GROUP LIMITED: OPERATING BUSINESS SEGMENTS

TABLE 68. MAYNE PHARMA GROUP LIMITED: PRODUCT PORTFOLIO

TABLE 69. MAYNE PHARMA GROUP LIMITED: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 70. MAYNE PHARMA GROUP LIMITED: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 71. MAYNE PHARMA GROUP LIMITED: KEY STRATERGY

TABLE 72. PFIZER, INC.: COMPANY SNAPSHOT

TABLE 73. PFIZER, INC.: OPERATING BUSINESS SEGMENTS

TABLE 74. PFIZER, INC.: PRODUCT PORTFOLIO

TABLE 75. PFIZER, INC.: SALES BY BUSINESS SEGMENTS (2021-2023)

TABLE 76. PFIZER, INC.: SALES BY GEOGRAPHIC SEGMENTS (2021-2023)

TABLE 77. PFIZER, INC.: KEY STRATERGY

LIST OF FIGURES

FIGURE 1. BARGAINING POWER OF SUPPLIERS

FIGURE 2. BARGAINING POWER OF BUYERS

FIGURE 3. DEGREE OF COMPETITION

FIGURE 4. THREAT OF SUBSTITUTE

FIGURE 5. THREAT OF NEW ENTRANTS

FIGURE 6. MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY ACNE TYPE, 2023-2030, (MILLION USD)

FIGURE 7. INFLAMMATORY ACNE , MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 8. NON-INFLAMMATORY ACNE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 9. MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY FORMULATION, 2023-2030, (MILLION USD)

FIGURE 10. TOPICAL MEDICATIONS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 11. ORAL MEDICATIONS , MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 12. MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY THERAPEUTIC CLASS, 2023-2030, (MILLION USD)

FIGURE 13. RETINOIDS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 14. ANTIBIOTICS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 15. SALICYLIC ACID, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 16. BENZOYL PEROXIDE, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 17. OTHERS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 18. MIDDLE EAST PROFESSIONAL ACNE MEDICATION MARKET VALUE, BY DISTRIBUTION CHANNEL, 2023-2030, (MILLION USD)

FIGURE 19. MED SPA, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 20. AESTHETICIAN, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 21. DERMATOLOGIST, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 22. OTHER PROFESSIONAL CHANNELS, MARKET VALUE, 2023-2030, (MILLION USD)

FIGURE 23. ALMIRALL SA: NET SALES, (2021-2023)

FIGURE 24. ALMIRALL SA: PRIMARY MARKET COMPETITORS

FIGURE 25. BAUSCH HEALTH COMPANIES, INC.: NET SALES, (2021-2023)

FIGURE 26. BAUSCH HEALTH COMPANIES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 27. GLAXOSMITHKLINE PLC (GSK): NET SALES, (2021-2023)

FIGURE 28. GLAXOSMITHKLINE PLC (GSK): PRIMARY MARKET COMPETITORS

FIGURE 29. GALDERMA S.A.: NET SALES, (2021-2023)

FIGURE 30. GALDERMA S.A.: PRIMARY MARKET COMPETITORS

FIGURE 31. SUN PHARMACEUTICAL INDUSTRIES LIMITED: NET SALES, (2021-2023)

FIGURE 32. SUN PHARMACEUTICAL INDUSTRIES LIMITED: PRIMARY MARKET COMPETITORS

FIGURE 33. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, (2021-2023)

FIGURE 34. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRIMARY MARKET COMPETITORS

FIGURE 35. JOHNSON AND JOHNSON: NET SALES, (2021-2023)

FIGURE 36. JOHNSON AND JOHNSON: PRIMARY MARKET COMPETITORS

FIGURE 37. STRATA SKIN SCIENCES, INC.: NET SALES, (2021-2023)

FIGURE 38. STRATA SKIN SCIENCES, INC.: PRIMARY MARKET COMPETITORS

FIGURE 39. MAYNE PHARMA GROUP LIMITED: NET SALES, (2021-2023)

FIGURE 40. MAYNE PHARMA GROUP LIMITED: PRIMARY MARKET COMPETITORS

FIGURE 41. PFIZER, INC.: NET SALES, (2021-2023)

FIGURE 42. PFIZER, INC.: PRIMARY MARKET COMPETITOR

KEY PLAYERS

  • Almirall SA

  • Bausch Health Companies, Inc.

  • GlaxoSmithKline Plc (GSK)

  • Galderma SA

  • Sun Pharmaceutical Industries Limited

  • Teva Pharmaceutical Industries Ltd.

  • Johnson & Johnson

  • STRATA Skin Sciences, Inc.

  • Mayne Pharma Group Limited

  • Pfizer, Inc 


Frequently Asked Questions
What will be the worth of the Middle East professional acne medication market by the end of 2030?

According to the report published by Next Move Consulting, the Middle East professional acne medication market business is expected to hit at USD 125.73 million by 2030.

What are the leading companies in the Middle East professional acne medication market?

The Middle East professional acne medication industry includes several market players such as Almirall SA, Bausch Health Companies, Inc., GlaxoSmithKline Plc (GSK), Galderma SA, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Johnson & Johnson, STRATA Skin Sciences, Inc., Mayne Pharma Group Limited, and Pfizer, Inc., and others.

What are the market segmentations and scope of the study for the Middle East professional acne medication industry?

Middle East professional acne medication market share is segmented based on acne type, formulation, therapeutic class, distribution channel, and geography.

What are the factors that are driving the growth of the professional acne medication market in Middle East?

The factors driving the growth of the professional acne medication market in Middle East include a surge in the demand for cosmetic dermatology treatments and a growing demand for professional acne treatments.

What is restraining the growth of the Middle East professional acne medication market?

The cost barriers are prominent restraining factors in Middle East's posing a significant challenge to its expansion.